Morgan Stanley’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-155,462
| Closed | -$247K | – | 8072 |
|
|
2024
Q1 | $247K | Sell |
155,462
-165,460
| -52% | -$245K | ﹤0.01% | 5649 |
|
|
2023
Q4 | $276K | Sell |
320,922
-156,318
| -33% | -$137K | ﹤0.01% | 5824 |
|
|
2023
Q3 | $511K | Sell |
477,240
-420,892
| -47% | -$871K | ﹤0.01% | 5163 |
|
|
2023
Q2 | $2.33M | Buy |
898,132
+41,823
| +5% | +$149K | ﹤0.01% | 4322 |
|
|
2023
Q1 | $3.49M | Buy |
856,309
+194,276
| +29% | +$898K | ﹤0.01% | 4074 |
|
|
2022
Q4 | $3.32M | Buy |
662,033
+114,974
| +21% | +$721K | ﹤0.01% | 4101 |
|
|
2022
Q3 | $7.16M | Sell |
547,059
-44,165
| -7% | -$669K | ﹤0.01% | 3322 |
|
|
2022
Q2 | $7.58M | Buy |
591,224
+10,520
| +2% | +$146K | ﹤0.01% | 3364 |
|
|
2022
Q1 | $8.86M | Buy |
580,704
+286,737
| +98% | +$4.47M | ﹤0.01% | 3049 |
|
|
2021
Q4 | $5.21M | Buy |
293,967
+151,219
| +106% | +$2.9M | ﹤0.01% | 3679 |
|
|
2021
Q3 | $3M | Sell |
142,748
-24,027
| -14% | -$529K | ﹤0.01% | 4231 |
|
|
2021
Q2 | $3.29M | Sell |
166,775
-75,795
| -31% | -$1.77M | ﹤0.01% | 4197 |
|
|
2021
Q1 | $7.05M | Buy |
242,570
+32,287
| +15% | +$904K | ﹤0.01% | 3045 |
|
|
2020
Q4 | $6.37M | Buy |
210,283
+57,234
| +37% | +$1.25M | ﹤0.01% | 3003 |
|
|
2020
Q3 | $2.44M | Sell |
153,049
-32,472
| -18% | -$592K | ﹤0.01% | 3478 |
|
|
2020
Q2 | $3.66M | Buy |
185,521
+182,634
| +6,326% | +$3.49M | ﹤0.01% | 2993 |
|
|
2020
Q1 | $35K | Sell |
2,887
-42,864
| -94% | -$700K | ﹤0.01% | 5592 |
|
|
2019
Q4 | $846K | Buy |
45,751
+24,029
| +111% | +$351K | ﹤0.01% | 4629 |
|
|
2019
Q3 | $301K | Buy |
21,722
+21,697
| +86,788% | +$326K | ﹤0.01% | 4930 |
|
|
2019
Q2 | $0 | Buy |
+25
| New | +$366 | ﹤0.01% | 6793 |
|
Morgan Stanley's NGM Position: Q2 2024 in Review
Morgan Stanley sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 155,462 shares — an estimated $247K sold.
Morgan Stanley first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $8.86M in Q1 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Morgan Stanley reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 155,462 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $247K.
- Morgan Stanley first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Morgan Stanley's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $8.86M in Q1 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.